View Older Stories

Mar 16, 2026 06:44AM Xenon Pharmaceuticals (XENE) PT Lowered to $63 at Wedbush

Mar 12, 2026 04:40PM Xenon Pharmaceuticals (XENE) PT Raised to $77 at BofA Securities

Mar 10, 2026 05:41AM Rapport Therapeutics (RAPP) Reiterated at Market Outperform by Citizens on RAP-219 Data

Mar 9, 2026 03:52PM Xenon Pharmaceuticals (XENE) PT Raised to $100 at Jefferies

Mar 9, 2026 02:47PM Xenon Pharmaceuticals (XENE) PT Raised to $90 at Guggenheim

Mar 9, 2026 02:21PM Xenon Pharmaceuticals (XENE) PT Raised to $74 at Bloom Burton & Co.

Mar 9, 2026 12:20PM Xenon Pharmaceuticals (XENE) PT Raised to $97 at Baird

Mar 9, 2026 10:10AM Xenon Pharmaceuticals (XENE) PT Raised to $77 at BofA Securities

Mar 9, 2026 09:30AM Xenon Pharmaceuticals (XENE) PT Raised to $89 at Stifel

Mar 9, 2026 09:18AM Jefferies Reiterates Buy Rating on Xenon Pharmaceuticals (XENE): "We see a +50-75% stock move"

Mar 9, 2026 08:26AM William Blair Reiterates Outperform Rating on Xenon Pharmaceuticals (XENE): "we see further room for upside"

Mar 9, 2026 08:23AM Stifel Reiterates Buy Rating on Xenon Pharmaceuticals (XENE)

Mar 9, 2026 08:06AM Baird Reiterates Outperform Rating on Xenon Pharmaceuticals (XENE): "Buyers on best-in-disease Phase 3 results"

Mar 9, 2026 07:27AM Stifel on Xenon Pharmaceuticals (XENE): 'we think the results here could lead investors to reconsider their peak penetration and peak sales assumptions'

Mar 9, 2026 06:55AM Xenon Pharmaceuticals (XENE) Halted, News Pending

Feb 26, 2026 05:16PM Xenon Pharmaceuticals (XENE) Misses Q4 EPS by 12c

Feb 24, 2026 09:00AM Wolfe Research Starts Xenon Pharmaceuticals (XENE) at Outperform, Top Pick

Feb 9, 2026 04:22PM Xenon Pharmaceuticals (XENE) PT Raised to $66 at Stifel

Jan 12, 2026 08:33AM Xenon Pharmaceuticals expects key drug trial results in March

Jan 9, 2026 07:33AM Xenon Pharmaceuticals (XENE) Reiterated at Overweight by JPMorgan

Jan 5, 2026 08:04AM Xenon Pharmaceuticals (XENE) PT Raised to $55 at Cantor Fitzgerald

Dec 26, 2025 08:18AM Stifel Reiterates Xenon Pharmaceuticals (XENE) at Buy following Biohaven's failure

Dec 19, 2025 09:06AM TD Cowen on Biotechnology: '10+ Potential "Thome Run" Catalysts To Watch In 2026'

Nov 16, 2025 03:00PM Where can biotech stocks go from here? RBC answers

Nov 4, 2025 09:06AM Cantor Fitzgerald Reiterates Overweight Rating on Xenon Pharmaceuticals (XENE)

Nov 3, 2025 04:03PM Xenon Pharmaceuticals (XENE) Reports In-Line Q3 EPS

Oct 7, 2025 09:08AM Stifel Reiterates Buy Rating on Xenon Pharmaceuticals (XENE)

Sep 11, 2025 08:18AM RBC Capital on Biotech Shares: 'Company-Specific Volatility For Quality Names May Be Overdone'

Sep 3, 2025 02:42AM Wells Fargo Assumes Xenon Pharmaceuticals (XENE) at Overweight

Aug 11, 2025 04:04PM Xenon Pharmaceuticals (XENE) Tops Q2 EPS by $2.06

Jun 30, 2025 06:50AM H.C. Wainwright Reiterates Buy Rating on Xenon Pharmaceuticals (XENE)

Jun 27, 2025 04:02PM Xenon Pharmaceuticals (XENE) joins Russell 2000 and 3000

Jun 24, 2025 08:31AM Xenon Pharmaceuticals (XENE) Announces Appointment of Darren Cline as Chief Commercial Officer

Jun 13, 2025 09:03AM Xenon Pharmaceuticals (XENE) PT Raised to $57 at RBC Capital

May 14, 2025 06:14AM Evercore ISI Starts Xenon Pharmaceuticals (XENE) at Outperform

May 13, 2025 09:46AM Xenon Pharmaceuticals (XENE) PT Lowered to $55 at RBC Capital

May 13, 2025 09:20AM Xenon Pharmaceuticals (XENE) PT Lowered to $60 at Stifel

May 13, 2025 07:52AM Cantor Fitzgerald Reiterates Overweight Rating on Xenon Pharmaceuticals (XENE)

May 13, 2025 07:43AM Xenon Pharmaceuticals (XENE) Tops Q1 EPS by 8c

May 13, 2025 07:29AM Xenon Pharmaceuticals (XENE) PT Lowered to $55 at Needham

May 7, 2025 04:30AM Chardan Capital Markets Starts Xenon Pharmaceuticals (XENE) at Buy

Apr 12, 2025 04:00AM Biotech sector Q1 earnings preview from RBC Capital Markets

Mar 17, 2025 07:06AM Cantor Fitzgerald says 15% of biotech companies down 40% or more

Feb 27, 2025 04:19PM Xenon Pharmaceuticals (XENE) Tops Q4 EPS by 1c

Feb 11, 2025 04:17AM Deutsche Bank Starts Xenon Pharmaceuticals (XENE) at Buy

Jan 13, 2025 08:33AM Xenon Pharmaceuticals (XENE) Outlines Key Corporate Milestone Opportunities for 2025

Jan 6, 2025 10:35AM TD Cowen: '10 Potential "Thome Run" Catalysts to Watch in 2025'

Dec 21, 2024 10:00AM RBC report: Biotech faces both uncertainty and growth opportunities in 2025

Dec 12, 2024 06:43AM H.C. Wainwright Reiterates Buy Rating on Xenon Pharmaceuticals (XENE)

Dec 6, 2024 04:01PM Xenon Pharmaceuticals (XENE) Showcases New Long-Term Azetukalner Data from X-TOLE OLE Study in FOS at AES 2024

View Older Stories